secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2025-08-20T23:59:59+00:00
Accession:  0001664710-25-000073
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros receives FDA Orphan Drug designation for KER-065 in Duchenne muscular dystrophy
--------------------------------------------------------------------------------

- FDA granted Orphan Drug designation for KER-065, a TGF-ß family protein-targeting therapy for DMD.
- Designation provides potential 7-year market exclusivity, tax credits, and fee waivers if approved.
- KER-065 is advancing toward a Phase 2 clinical trial in patients with DMD, as stated by CEO.
- DMD affects fewer than 200,000 people in the U.S., qualifying for Orphan Drug status.
- Keros (KROS) is a clinical-stage biopharma focused on TGF-ß signaling disorders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000073/0001664710-25-000073-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471025000073/kros-20250820.htm
  HTML page:      https://secwatch.observer/filing/0001664710-25-000073

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer